Table 6. Top diseases associated with differentially expressed proteins in ASD with severe language impairment.
| Category | P-value | Proteins |
|---|---|---|
| Endocrine System Disorders | 5.93E-06–4.16E-02 | TUBB, COX5A, ANXA5, GSTP1, AHSG, ENO1, CCT5 |
| Neurological Disease | 3.19E-05–3.72E-02 | HNRNPA1, DLD, CALM1, TUBB, LGALS1, TPT1, ANXA5, DBI, GSTP1, H3F3C, CCT5, IDH2 |
| Lipid Metabolism | 6.25E-05–1.47E-02 | LGALS1, ANXA5, DBI, GSTP1 |
| Inflammatory Disease | 4.95E-04–4.17E-02 | HNRNPA1, LGALS1, ERH, ANXA5, GSTP1, AHSG, ENO1 |
| Developmental Disorder | 9.24E-04–1.06E-02 | HNRNPA1, DLD, CALM1, TUBB, IDH2 |
| Psychological Disorders | 4.61E-03–3.72E-02 | HNRNPA1, TUBB, LGALS1, TPT1, DBI, GSTP1 |
The list of 18 differentially expressed proteins identified via 2D-PAGE and LC-MS/MS analysis was uploaded for Ingenuity Pathway Analysis, and diseases associated with these proteins were predicted. P-values were calculated using Fisher’s exact test.